Verona Pharma plc Pdmr Dealing

 
TIDMVRP 
 
   LONDON, March 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces that, on March 22, 2019, Mr. Piers 
Morgan, CFO of the Company, purchased 20,132 ordinary shares of 5 pence 
each in the Company (the "Ordinary Shares") at a price of 64 pence per 
Ordinary Share and a total purchase price of GBP12,884.48  Following the 
acquisition, Mr. Morgan will have an interest in the Company of 113,207 
Ordinary Shares, representing 0.11% of the Company's issued share 
capital. 
 
   The purchase by Mr. Morgan brings the total purchases made by him this 
month to GBP32,884.46 and follows the purchases made by the Company's 
Chairman, Dr. David Ebsworth, earlier this month totaling approximately 
GBP50,000.00. 
 
   The notification set out below is provided in accordance with the 
requirements of the EU Market Abuse Regulation. 
 
 
 
 
1    Details of the person discharging managerial responsibilities/person 
      closely associated 
---  ---------------------------------------------------------------------- 
 
 a)   Name                                     Piers Morgan 
---  ---------------------------------------  ----------------------------- 
2    Reason for the notification 
---  ---------------------------------------------------------------------- 
     Position/status                          Chief Financial Officer 
 a) 
---  ---------------------------------------  ----------------------------- 
     Initial notification/Amendment           Initial notification 
 b) 
---  ---------------------------------------  ----------------------------- 
3    Details of the issuer, emission allowance market participant, 
      auction platform, auctioneer or auction monitor 
---  ---------------------------------------------------------------------- 
     Name                                     Verona Pharma plc 
 a) 
---  ---------------------------------------  ----------------------------- 
     LEI                                      213800EVI6O6J3TIAL06 
 b) 
---  ---------------------------------------  ----------------------------- 
 
 
 
 
 
 
4    Details of the transaction(s): section to be repeated 
      for (i) each type of instrument; (ii) each type of 
      transaction; (iii) each date; and (iv) each place 
      where transactions have been conducted 
---  ----------------------------------------------------------------------------------------------- 
                                                                   Ordinary Shares of 5 pence each 
 a)   Description of the financial instrument, type of instrument   GB00BYW2KH80 
      Identification code 
---  ------------------------------------------------------------  --------------------------------- 
                                                                   Piers Morgan purchased 20,132 
 b)   Nature of the transaction                                    Ordinary Shares 
---  ------------------------------------------------------------  --------------------------------- 
                                                                   Price(s)         Volume(s) 
 c) 
---  ------------------------------------------------------------  ---------  ---------------------- 
                                                                   64 pence   20,132 Ordinary Shares 
      Price(s) and volume(s)                                       per 
                                                                   Ordinary 
                                                                   Share 
---  ------------------------------------------------------------  ---------  ---------------------- 
 
 d)   Aggregated information                                        N/A 
      - Aggregated volume 
      - Price 
---  ------------------------------------------------------------  --------------------------------- 
     Date of the transaction                                       22 March 2019 
 e) 
---  ------------------------------------------------------------  --------------------------------- 
     Place of the transaction                                      London Stock Exchange, AIM 
 f) 
---  ------------------------------------------------------------  --------------------------------- 
 
 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer       info@veronapharma.com 
 Victoria Stewart, Director of Communications 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: +44 (0) 20 7710 7600 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison
(END) Dow Jones Newswires
March 25, 2019 03:00 ET (07:00 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024